Compare WAFU & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAFU | ERNA |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.1M |
| IPO Year | 2017 | 2021 |
| Metric | WAFU | ERNA |
|---|---|---|
| Price | $1.63 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.0K | ★ 1.2M |
| Earning Date | 07-31-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $0.15 |
| 52 Week High | $2.17 | $3.00 |
| Indicator | WAFU | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 27.60 |
| Support Level | $1.39 | $0.16 |
| Resistance Level | $1.75 | $0.35 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 14.79 | 12.78 |
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.